^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CUG288

    i
    Other names: TILKine-2, CUG288
    Associations

    News

    Trials
    Company:
    Cugene
    Drug class:
    IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    3years
    TILKine-2: A novel best-in-class tumor infiltrating lymphocyte (TIL) targeting engineered IL-2 with superior pre-clinical efficacy and safety for immunotherapy of cancer. (SITC 2021)
    Conclusions By targeting TILs, TILKine-2 demonstrated robust anti-tumor efficacy by preferentially inducing proliferation, expansion, and activation of intra-tumoral lymphocytes while reducing systemic toxicity and improving therapeutic window. In conclusion, TILKine-2 is a promising therapeutic agent for clinical development.
    Preclinical • Tumor-Infiltrating Lymphocyte • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • GZMB (Granzyme B)
    |
    CD8 expression
    |
    CUG288